China currently approves over eight disease-modifying therapies for multiple sclerosis, including Aubagio, Tecfidera, and Gilenya. High-efficacy options like Kesimpta and Mayzent are also available. Regulatory acceleration since 2018 facilitates rapid market entry for advanced biologics, stem cell injections, and sphingosine-1-phosphate modulators.
- First oral therapy: Aubagio (Teriflunomide) was approved in 2018 for relapsing forms.
- High-efficacy biologics: Kesimpta (Ofatumumab) offers targeted B-cell depletion via subcutaneous injection.
- S1P modulators: Gilenya, Mayzent, and Zeposia are approved for various relapsing stages.
- Reimbursement status: Most DMTs are included in the National Reimbursement Drug List.
Bookimed Expert Insight: Patients should focus on Class A Level III clinics like Yanda International Hospital in Beijing. These top-tier facilities integrate international protocols with Western medicine. Data shows specialists like Dr. Fan Yun Pin manage complex demyelinating diseases. They often provide access to therapies like Ocrevus, which may otherwise require traveling to Hong Kong.
Patient Consensus: Patients note that Gilenya is widely available in Beijing hospitals but requires significant paperwork. Many emphasize joining local WeChat groups to track real-time drug availability and insurance coverage updates.